Home » Cancer Topics » Skin Cancer
Skin Cancer
FEATURED CONTENT
Tumor-infiltrating lymphocytes can improve progression-free survival, when compared with ipilimumab, in patients with advanced melanoma, a phase 3 trial suggests.
First-line immune checkpoint inhibitors have improved survival in patients with metastatic melanoma but remain underused in this population.
Exposure to low-dose methotrexate is associated with an increased risk of melanoma, according to a meta-analysis of 17 studies.
Adding T-VEC to pembrolizumab does not improve survival in patients with advanced melanoma, a phase 3 study suggests.
Some disparities that existed before FDA approval persisted after approval, and some new disparities emerged after FDA approval.
SKIN CANCER NEWS Load More
Open
Next post in Skin Cancer
Close
Close more info about Comparable Outcomes With and Without Neoadjuvant Therapy in High-Risk Melanoma
Loading...
Close more info about Comparable Outcomes With and Without Neoadjuvant Therapy in High-Risk Melanoma
Loading...